{[ promptMessage ]}

Bookmark it

{[ promptMessage ]}

case study on gsk in developing countries.

case study on gsk in developing countries. - Case Study on...

Info iconThis preview shows pages 1–4. Sign up to view the full content.

View Full Document Right Arrow Icon
Case Study on: GlaxoSmithKline Case OBJECTIVE: GSK TO SUPPL Y ANTIRETROVIRALS AND ANTI-MALARIALS A T SUST AINABLE PREFERENTIAL PRICES F OR ELIGIBLE CUST OMERS IN THE LEAST DEVELOPED COUNTRIES AND ALL SUB-SAHARAN AFRICAN COUNTRIES . Eligible customers include the public sector , not-for -profit NGOs , aid agencies , UN agencies and international purchase funds such as the Global Fund to fight AIDS , TB and Malaria. Additi o nall y , be c au s e o f the gra v ity of the situation in sub-Saharan Africa, employers there wh o offer HIV/AIDS care and treatment directly to their staff through workplace clinics are also eligible . 1 | P a g e
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full Document Right Arrow Icon
MADE BY: JIGAR.R.RAJPURA X-01824544 Sustainable Preferential Pricing Ar r angements GlaxoSmithKline has of fer ed pr efer ential pricing for our HIV/AIDS medicines since 1997. They placed a high priority on their prices being sustainable. This means setting prices at levels that meet their costs, ther eby ensuring they can sustain supply of these high-quality pr oducts for as long as they are needed. The Pr omise In ‘Facing the Challenge’ it is promised to : extend pr efer ential pricing to mor e pr oducts, countries and customers; supply antiretr ovirals and anti-malarials at pr efer ential prices to public sector customers and not- for -pr ofit organisations in 63 countries all the Least Developed Countries of the world and all of sub- Saharan Africa; supply AR V therapy at pr efer ential prices to employers in sub-Saharan Africa who pr ovide HIV/AIDS car e and tr eatment dir e ctly to their staf f thr ough their own workplace clinics; make thier AR Vs and anti-malarials available at pr efer ential prices to inter national pur chase funds; set up pilot pr ojects with non-gover nmental organisations (NGOs) in five African countries to evaluate the impact ofof fering a mor e extensive range of medicines at pr efer ential prices; work on a case-by-case basis with middle income developing countries thr ough the AAI and unilaterally to make tr eatment mor e af for dable; continue established discounting arrangements for vaccine supply 2 | P a g e
Background image of page 2
work with genuine partners on other ways of making medicine mor e af for dable for developing countries. Progr ess They have concluded some 95 arrangements covering 31 countries for the supply of pr efer entially priced ARVs. Chart A outlines these partners by type and progr ess since the start of 2001. Nineteen of the supply agr eements have been thr ough the Accelerating Access Initiative (AAI). AAI is the partnership, established in 2000, between UN agencies and six pharmaceutical companies. Among the AAI partner countries ar e middle income developing countries that have shown str ong political will to tackle HIV/AIDS. These include Honduras, T rinidad and T obago, Romania, and Chile. The AAI has had an important catalytic ef fect. A further 59 countries have expr essed inter est in joining. As a r esult of these initiatives, a tenfold incr ease in shipments of pr efer entially priced Combivir to the
Background image of page 3

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full Document Right Arrow Icon
Image of page 4
This is the end of the preview. Sign up to access the rest of the document.

{[ snackBarMessage ]}